Could a loss of α-synuclein function put dopaminergic neurons at risk?

Journal of Neurochemistry

Volumn 89, Issue 6, 2004, Pages 1318-1324

  Perez, Ruth G ^a   Hastings, Teresa G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Chaperone; Dephosphorylation; Mitochondria; Parkinson's disease; Quinone; Tyrosine hydroxylase

Indexed keywords

ALPHA SYNUCLEIN; CHAPERONE; DOPAMINE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; TYROSINE 3 MONOOXYGENASE;

CELL VACUOLE; DEPHOSPHORYLATION; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; ENZYME BINDING; ENZYME INHIBITION; LEWY BODY; MITOCHONDRION; NEURITE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RISK FACTOR; SHORT SURVEY; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE; DROSOPHILA; HUMANS; MOLECULAR CHAPERONES; NERVE TISSUE PROTEINS; NEURONS; PARKINSON DISEASE; SYNUCLEINS; TYROSINE 3-MONOOXYGENASE;

EID: 3042655068     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02423.x     Document Type: Short Survey

References (79)

1. Abeliovich A., Schmitz Y., Farinas I. et al. (2000) Mice lacking α-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25, 239-252.
2. Ara J., Przedborski S., Naini A. B., Jackson-Lewis V., Trifiletti R. R., Horwitz J. and Ischiropoulos H. (1998) Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Proc. Natl Acad. Sci. USA 95, 7659-7663.
3. Auluck P. K., Chan H. Y., Trojanowski J. Q., Lee V. M. and Bonini N. M. (2002) Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295, 865-868.
4. Berman S. B. and Hastings T. G. (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson's disease. J. Neurochem. 73, 1127-1137.
5. Bodles A. M., Guthrie D. J., Greer B. and Irvine G. B. (2001) Identification of the region of non-Abeta component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity. J. Neurochem. 78, 384-395.
6. Braak H. and Braak E. (2000) Pathoanatomy of Parkinson's disease. J. Neurol. 247 Suppl. 2, II3-10.
7. Cabin D. E., Shimazu K., Murphy D. et al. (2002) Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking α-synuclein. J. Neurosci. 22, 8797-8807.
8. Conway K. A., Harper J. D. and Lansbury P. T. (1998) Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease. Nat. Med. 4, 1318-1320.
9. Conway K. A., Rochet J. C., Bieganski R. M. and Lansbury P. T. Jr (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct. Science 294, 1346-1349.
10. Culvenor J. G., McLean C. A., Cutt S., Campbell B. C. V., Maher F., Jakala P., Hartmann T., Beyreuther K., Masters C. L. and Li Q.-X. (1999) Non-A{beta} component of Alzheimer's Disease amyloid (NAC) revisited: NAC and α-Synuclein are not associated with Aβ amyloid. Am. J. Pathol. 155, 1173-1181.
11. Dauer W., Kholodilov N., Vila M. et al. (2002) Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl Acad. Sci. USA 99, 14524-14529.
12. Davidson W. S., Jonas A., Clayton D. F. and George J. M. (1998) Stabilization of α-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449.
13. Feany M. B. and Bender W. W. (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398.
14. Ferrer I., Blanco R., Carmona M., Puig B., Barrachina M., Gomez C. and Ambrosio S. (2001) Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies. J. Neural Transm. 108, 1383-1396.
15. Galvin J. E., Lee V. M. and Trojanowski J. Q. (2001a) Synucleinopathies: clinical and pathological implications. Arch. Neurol. 58, 186-190.
16. Galvin J. E., Schuck T. M., Lee V. M. and Trojanowski J. Q. (2001b) Differential expression and distribution of α-, β-, and γ-synuclein in the developing human substantia nigra. Exp. Neurol. 168, 347-355.
17. George J. M., Jin H., Woods W. S. and Clayton D. F. (1995) Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361-372.
18. Ghee M., Fournier A. and Mallet J. (2000) Rat α-synuclein interacts with Tat binding protein 1, a component of the 26S proteasomal complex. J. Neurochem. 75, 2221-2224.
19. 2 and hydroxyl radicals but not glutathione-protein- mixed disulfides. J. Neurochem. 82, 66-74.
20. Goedert M. (1997) Familial Parkinson's disease. The awakening of α-synuclein. Nature 388, 232-233.
21. Graham D. G., Tiffany S. M., Bell W. R. Jr and Gutknecht W. F. (1978) Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644-653.
22. Hashimoto M., Takeda A., Hsu L. J., Takenouchi T. and Masliah E. (1999) Role of cytochrome c as a stimulator of α-synuclein aggregation in Lewy body disease. J. Biol. Chem. 274, 28849-28852.
23. Hashimoto M., Rockenstein E., Mante M., Mallory M. and Masliah E. (2001) Beta-Synuclein inhibits α-synuclein aggregation: a possible role as an anti-parkinsonian factor. Neuron 32, 213-223.
24. Hashimoto M., Takenouchi T., Rockenstein E. and Masliah E. (2003) α-Synuclein up-regulates expression of caveolin-1 and down-regulates extracellular signal-regulated kinase activity in B103 neuroblastoma cells: role in the pathogenesis of Parkinson's disease. J. Neurochem. 85, 1468-1479.
25. Hastings T. G. and Berman S. B. (1999) Dopamine-induced toxicity and quinone modification of proteins: Implications for Parkinson's disease. In: Role of Catechol Quinone Species in Cellular Toxicity (Creveling, C. R., ed.), pp. 69-89. F.P. Graham Publishing, Inc., Johnson City, TN.
26. Hastings T. G., Lewis D. A. and Zigmond M. J. (1996) Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl Acad. Sci. USA 93, 1956-1961.
27. Haycock J. W. (1990) Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, and 40. J. Biol. Chem. 265, 11682-11691.
28. Hsu L. J., Mallory M., Xia Y., Veinbergs I., Hashimoto M., Yoshimoto M., Thal L. J., Saitoh T. and Masliah E. (1998) Expression pattern of synucleins (non-Abeta component of Alzheimer's disease amyloid precursor protein/α-synuclein) during murine brain development. J. Neurochem. 71, 338-344.
29. Ichimura T., Isobe T., Okuyama T., Takahashi N., Araki K., Kuwano R. and Takahashi Y. (1988) Molecular cloning of cDNA coding for brain-specific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and tryptophan hydroxylases. Proc. Natl Acad. Sci. USA 85, 7084-7088.
30. Irizarry M. C., Kim T. W., McNamara M., Tanzi R. E., George J. M., Clayton D. F. and Hyman B. T. (1996) Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J. Neuropathol. Exp. Neurol. 55, 889-895.
31. Ischiropoulos H. (2003) Oxidative modifications of α-synuclein. Ann. NY Acad. Sci. 991, 93-100.
32. Itagaki C., Isobe T., Taoka M. et al. (1999) Stimulus-coupled interaction of tyrosine hydroxylase with 14-3-3 proteins. Biochemistry 38, 15673-15680.
33. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H. A., Kittel A. and Saitoh T. (1995) The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14, 467-475.
34. Iwata A., Maruyama M., Kanazawa I. and Nukina N. (2001) α-Synuclein affects the MAPK pathway and accelerates cell death. J. Biol. Chem. 276, 45320-45329.
35. Jenco J. M., Rawlingson A., Daniels B. and Morris A. J. (1998) Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by α- and β-synucleins. Biochemistry 37, 4901-4909.
36. Jensen P. H., Hager H., Nielsen M. S., Hojrup P., Gliemann J. and Jakes R. (1999) α-Synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J. Biol. Chem. 274, 25481-25489.
37. Kawamoto Y., Akiguchi I., Nakamura S., Honjyo Y., Shibasaki H. and Budka H. (2002) 14-3-3 proteins in Lewy bodies in Parkinson disease and diffuse Lewy body disease brains. J. Neuropathol. Exp. Neurol. 61, 245-253.
38. Kim T. D., Paik S. R., Yang C. H. and Kim J. (2000) Structural changes in α-synuclein affect its chaperone-like activity in vitro. Protein Sci. 9, 2489-2496.
39. Kleppe R., Toska K. and Haavik J. (2001) Interaction of phosphorylated tyrosine hydroxylase with 14-3-3 proteins: evidence for a phosphoserine 40-dependent association. J. Neurochem. 77, 1097-1107.
40. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J. T., Schols L. and Riess O. (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
41. Kuhn D. M., Aretha C. W. and Geddes T. J. (1999a) Peroxynitrite inactivation of tyrosine hydroxylase: mediation by sulfhydryl oxidation, not tyrosine nitration. J. Neurosci. 19, 10289-10294.
42. Kuhn D. M., Arthur R. E. Jr, Thomas D. M. and Elferink L. A. (1999b) Tyrosine hydroxylase is inactivated by catechol-quinones and converted to a redox-cycling quinoprotein: possible relevance to Parkinson's disease. J. Neurochem. 73, 1309-1317.
43. Kuljis R. O., Martin-Vasallo P. and Peress N. S. (1989) Lewy bodies in tyrosine hydroxylase-synthesizing neurons of the human cerebral cortex. Neurosci. Lett. 106, 49-54.
44. Kumer S. C. and Vrana K. E. (1996) Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem. 67, 443-462.
45. Larsen K. E., Fon E. A., Hastings T. G., Edwards R. H. and Sulzer D. (2002) Methamphetamine-induced degeneration of dopaminergic neurons involves autophagy and upregulation of dopamine synthesis. J. Neurosci. 22, 8951-8960.
46. LaVoie M. J. and Hastings T. G. (1999) Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J. Neurosci. 19, 1484-1491.
47. Layfield R., Fergusson J., Aitken A., Lowe J., Landon M. and Mayer R. J. (1996) Neurofibrillary tangles of Alzheimer's disease brains contain 14-3-3 proteins. Neurosci. Lett. 209, 57-60.
48. Lee F. J., Liu F., Pristupa Z. B. and Niznik H. B. (2001) Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. FASEB J. 15, 916-926.
49. Lindgren N., Goiny M., Herrera-Marschitz M., Haycock J. W., Hokfelt T. and Fisone G. (2002) Activation of extracellular signal-regulated kinases 1 and 2 by depolarization stimulates tyrosine hydroxylase phosphorylation and dopamine synthesis in rat brain. Eur. J. Neurosci. 15, 769-773.
50. Lotharius J. and Brundin P. (2002) Pathogenesis of Parkinson's disease: dopamine, vesicles and α-synuclein. Nat. Rev. Neurosci. 3, 932-942.
51. Lotharius J. and O'Malley K. L. (2000) The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 275, 38581-38588.
52. Manning-Bog A. B., McCormack A. L., Li J., Uversky V. N., Fink A. L. and Di Monte D. A. (2002) The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice: paraquat and α-synuclein. J. Biol. Chem. 277, 1641-1644.
53. Maroteaux L., Campanelli J. T. and Scheller R. H. (1988) Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 8, 2804-2815.
54. Murphy D. D., Rueter S. M., Trojanowski J. Q. and Lee V. M. (2000) Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci. 20, 3214-3220.
55. Muslin A. J. and Xing H. (2000) 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell Signal 12, 703-709.
56. Nakashima S. and Ikuta F. (1984) Tyrosine hydroxylase protein in Lewy bodies of parkinsonian and senile brains. J. Neurol. Sci. 66, 91-96.
57. Neystat M., Lynch T., Przedborski S., Kholodilov N., Rzhetskaya M. and Burke R. E. (1999) α-Synuclein expression in substantia nigra and cortex in Parkinson's disease. Mov. Disord. 14, 417-422.
58. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J. and Wolozin B. (1999) α-Synuclein shares physical and functional homology with 14-3-3 proteins. J. Neurosci. 19, 5782-5791.
59. Perez R. G. and Zigmond M. J. (2000) α-Synuclein may be a chaperone for tyrosine hydroxylase. Society for Neuroscience, Washington, DC. Online, Program Number 84.15. [www document]. URL http://isfn.scholarone.com/itin2000.
60. Perez R. G., Waymire J. C., Lin E., Liu J. J., Guo F. and Zigmond M. J. (2002) A role for α-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090-3099.
61. Polymeropoulos M. H., Lavedan C., Leroy E. et al. (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
62. Rabinovic A. D., Lewis D. A. and Hastings T. G. (2000) Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience 101, 67-76.
63. Ribeiro C. S., Carneiro K., Ross C. A., Menezes J. R. and Engelender S. (2002) Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by α-synuclein. J. Biol. Chem. 277, 23927-23933.
64. Rockenstein E., Hansen L. A., Mallory M., Trojanowski J. Q., Galasko D. and Masliah E. (2001) Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 914, 48-56.
65. Saito S., Sakagami H. and Kondo H. (2000) Localization of mRNAs for phospholipase D (PLD) type 1 and 2 in the brain of developing and mature rat. Brain Res. Dev. Brain Res. 120, 41-47.
66. Schluter O. M., Fornai F., Alessandri M. G., Takamori S., Geppert M., Jahn R. and Sudhof T. C. (2003) Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 118, 985-1002.
67. Sherer T. B., Betarbet R., Stout A. K., Lund S., Baptista M., Panov A. V., Cookson M. R. and Greenamyre J. T. (2002) An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered α-synuclein metabolism and oxidative damage. J. Neurosci. 22, 7006-7015.
68. Shimura H., Schlossmacher M. G., Hattori N., Frosch M. P., Trockenbacher A., Schneider R., Mizuno Y., Kosik K. S. and Selkoe D. J. (2001) Ubiquitination of a new form of α-synuclein by parkin from human brain: implications for Parkinson's disease. Science 293, 263-269.
69. Singleton A. B., Farrer M., Johnson J. et al. (2003) α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
70. Spillantini M. G., Schmidt M. L., Lee V. M., Trojanowski J. Q., Jakes R. and Goedert M. (1997) α-Synuclein in Lewy bodies. Nature 388, 839-840.
71. Stathakis D. G., Burton D. Y., Mclvor W. E., Krishnakumar S., Wright T. R. and O'Donnell J. M. (1999) The catecholamines up (Catsup) protein of Drosophila melanogaster functions as a negative regulator of tyrosine hydroxylase activity. Genetics 153, 361-382.
72. Teismann P., Tieu K., Choi D. K., Wu D. C., Naini A., Hunot S., Vila M., Jackson-Lewis V. and Przedborski S. (2003) Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl Acad. Sci. USA 100, 5473-5478.
73. Toska K., Kleppe R., Armstrong C. G., Morrice N. A., Cohen P. and Haavik J. (2002) Regulation of tyrosine hydroxylase by stress-activated protein kinases. J. Neurochem. 83, 775-783.
74. Ueda K., Fukushima H., Masliah E., Xia Y., Iwai A., Yoshimoto M., Otero D. A., Kondo J., Ihara Y. and Saitoh T. (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl Acad. Sci. USA 90, 11282-11286.
75. Wersinger C., Prou D., Vernier P. and Sidhu A. (2003) Modulation of dopamine transporter function by α-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. 17, 2151-2153.
76. Withers G. S., George J. M., Banker G. A. and Clayton D. F. (1997) Delayed localization of synelfin (synuclein, NACP) to presynaptic terminals in cultured rat hippocampal neurons. Brain Res. Dev. Brain Res. 99, 87-94.
77. Xu J., Kao S. Y., Lee F. J., Song W., Jin L. W. and Yankner B. A. (2002) Dopamine-dependent neurotoxicity of α-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat. Med. 8, 600-606.
78. Yang F., Ueda K., Chen P., Ashe K. H. and Cole G. M. (2000) Plaque-associated α-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. Brain Res. 853, 381-383.
79. Yoshimoto M., Iwai A., Kang D., Otero D. A., Xia Y. and Saitoh T. (1995) NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. Proc. Natl Acad. Sci. USA 92, 9141-9145.